ClinicalTrials.gg
TerminatedNCT04107675BOSTON-4Updated Oct 3, 2023Results posted

A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)

A Phase 2 interventional study of Liposomal Cyclosporine A and Liposomal Placebo in Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic and Stem Cell Transplant Complications, sponsored by Zambon SpA. Terminated at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-03.

Sponsored by Zambon SpA · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to the low number of patients recruited and the slow enrollment pace of patients, on 18 March 2022, the sponsor decided to terminate the BOSTON-4 safety and tolerability trial ahead of time.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Bronchiolitis Obliterans Syndrome with a site in France — 13 open to participants now, 17 under way, 5 of them phase 3. Bronchiolitis Obliterans Syndrome · France.

Enrollment
57th of 58
6 · median 105
Started
2020
with 3 others
Phase 2
11 of 68
4 open now
Registered
53rd of 68
by date

Among the 68 studies in Bronchiolitis Obliterans Syndrome with a site in France, this one is the 57th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2020, is one of 11 in phase 2, and was the 53rd registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

13 of the 68 studies in Bronchiolitis Obliterans Syndrome with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Bronchiolitis Obliterans Syndrome with a site in France, or all of them as a file.
02

Study summary

Primary Objective:

The primary objective of this study is to assess the tolerability and safety of two dose levels of aerosolized L-CsA vs placebo in addition to SoC therapy for BOS in adult allo-HSCT recipients.

Secondary Objectives:

The secondary objectives of this study are to assess PK and exploratory efficacy and quality of life of two dose levels of aerosolized L-CsA vs placebo in addition to SoC therapy for BOS in adult allo-HSCT recipients.

Read the detailed description

This is a Phase II prospective, multi-center, single-blind, randomized clinical trial evaluating safety and tolerability in adult recipients of an allo-HSCT with BOS. Twenty-four patients were planned for enrollment; but, at the time of the premature termination of this study, a total of 11 patients were screened for the study, of whom 5 patients did not fulfill the inclusion criteria and 6 patients were randomly allocated 1:1:1 in 3 treatment groups (L-CsA 10 mg + SoC, L-CsA 5 mg + SoC, or placebo + SoC).

A total of 18 centers in 3 countries (France, Germany, and Spain) in Europe were initiated for this multi-center study.

IMP was administered for up to 12 weeks treatment period. With low patient recruitment, the BOSTON-4 safety and tolerability study was terminated early by the sponsor on 18 March 2022. This decision was made after a careful and due diligent analysis performed by Zambon of the study status and considering the impact of coronavirus disease 2019 (COVID-19) pandemic on sites activities. From the beginning of the study, in December 2019, only 6 patients were randomized. So it was estimated that continuing the trial with the current protocol and setting would have taken another 9 years for the study to complete.

03

Conditions studied

  • Bronchiolitis Obliterans Syndrome (BOS)
  • GVHD, Chronic
  • Stem Cell Transplant Complications

Keywords

  • stem cell
  • hematopoietic transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >/= 18 years
  2. Patient must have a history of HSCT, regardless of source of stem cell or donor or indication for allogeneic HSCT
  3. Documented diagnosis of chronic (cGvHD) in any organ other than the lung. If BOS is the only manifestation of cGvHD, lung must have been performed before entering the trial to confirm BOS diagnosis.
  4. Confirmed diagnosis of BOS Score 1 [Jagasia et al. 2015] within > 6 months and \< 3 years after allo-HSCT:

    /FVC \< 0.7 at Screening Visit AND Post-bronchodilator FEV1 >/= 60 and ≤ 79% predicted at Screening Visit AND

    • 10% decline of FEV1 % predicted within 24 months prior to Screening Visit AND Absence of acute infection in the respiratory tract.
  5. Patient must be capable of understanding the purposes and risks of the study, has given written , and agrees to comply with the study requirements.
  6. Patient is capable of aerosol inhalation.
  7. Women of must have a negative serum or urine pregnancy test at screening and at randomization visit.

Exclusion criteria

Exclusion Criteria:

  1. Active bacterial, viral (as confirmed by multiplex PCR) or fungal infection not successfully resolved at least 4 weeks prior to the Screening Visit.
  2. Chronic renal dysfunction with serum creatinine >/= 2.5 mg/dL or need for renal dialysis.
  3. Chronic hepatic dysfunction with serum total > 5x (ULN), transaminases > 5x ULN, or alkaline phosphatase > 5x ULN.
  4. Evidence of relapse of the primary which warranted bone marrow transplant.
  5. Use of azithromycin within 4 weeks prior to Randomization (Visit 1).
  6. Use of zafirlukast during the study period.
  7. Chronic oxygen use or use of non-invasive ventilation.
  8. Active smokers (i.e. any kind of inhaled nicotine consumption).
  9. Pregnant women or women who are unwilling to use appropriate to avoid pregnancy over the course of the clinical trial.
  10. Women who are currently breastfeeding.
  11. Known to L-CsA or to cyclosporine A.
  12. Patients who do not tolerate administration of inhaled bronchodilators (e.g., salbutamol).
  13. Patients with life-expectancy of less than 6 months.
  14. Treatments with other Medicinal Products (IMPs) or previous therapies within four weeks or five times half-life of the drug, whichever is longer prior to screening and during the study. Participation in registries, considering the before, is allowed.
  15. Psychiatric disorders or altered mental status precluding understanding of the process and/or completion of the necessary procedures.
  16. Any co-existing medical condition that in the Investigator's judgment will substantially increase the risk associated with the patient's participation in the clinical trial.
  17. Pre-scheduled hospitalizations, surgeries or interventions planned to be performed after obtaining Informed Consent for this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    L-CsA 10 mg plus Standard of Care

    Liposomal Cyclosporine A 10 mg (10 mg/2.5 mL) bid, once in the morning and once in the evening, for up to 12 weeks. The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 8 to 13 minutes for the 0- and 10-mg doses. Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication

    Drug: Liposomal Cyclosporine A

  • Experimental
    L-CsA 5 mg plus Standard of Care

    Liposomal Cyclosporine A 5 mg (5 mg/1.25 mL) bid, once in the morning and once in the evening, for up to 12 weeks. The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 5 to 10 minutes for the 5-mg dose. Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication

    Drug: Liposomal Cyclosporine A

  • Placebo comparator
    Liposomal Placebo plus Standard of Care

    Liposomal Placebo 2.5 mL (0 mg L-CsA/2.5 mL) bid, once in the morning and once in the evening, for up to 12 weeks. The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 8 to 13 minutes for the 0- and 10-mg doses. Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication

    Drug: Liposomal Placebo

Interventions

  • Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm

    Also known as: L-CsA

  • DrugLiposomal Placebo

    Liposomal Placebo is administered with the same new technology of nebulizing liquid drugs used for L-CsA, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Number of Local Tolerability Events of Interest From Baseline to Visit 3 (Week 4)

    The local tolerability events of interest taken into consideration were: Cough, Wheezing, Bronchospasm, Throat irritation and Change from baseline in FEV1 to Visit 3.

    Time frame: at Week 4 (visit 3)

  2. Number of Participants With AE and sAE of Different Level of Severity During the First 4 Weeks of Treatment

    An adverse event (AE) is any untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.

    Time frame: During the first 4 weeks of treatment

Secondary outcomes

  1. Number of Local Tolerability Events of Interest From Baseline to Week 12

    The local tolerability events of interest taken into consideration were: Cough, Wheezing, Bronchospasm, Throat irritation and Change from baseline in FEV1 to Visit 3.

    Time frame: at Week 12

  2. Number of Participants With AE and sAE of Different Level of Severity During the First 12 Weeks of Treatment

    An adverse event (AE) is any untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.

    Time frame: During the first 12 weeks of treatment

  3. CsA Whole Blood Concentrations and CsA Whole Blood Trough Levels

    Whole Blood concentrations (Week 0) are at pre-dose, directly after end of inhalation, 15, 30, and 45 minutes, and 1, 1.5, 2, and 4 hours after end of inhalation, and whole blood trough levels (CsA concentration) at Weeks 2, 4, 8, and 12 were calculated.

    Time frame: Weeks 0 (pre-dose, directly after end of inhalation, 15, 30, 45, 60 min, 1.5 h, 2h, 4h), 2, 4, 8, and 12

07

Results

Posted Oct 3, 2023
Limitations and caveats
From the beginning of the trial, only 6 patients were enrolled. Due to the low number of patients recruited so far and the slow enrolment pace of patients, on 18 March 2022, the sponsor decided to terminate the BOSTON-4 safety and tolerability trial early. This decision was made after the Sponsor performed a careful and due diligent analysis of the current study status and considered the impact of the coronavirus disease 2019 (COVID-19) pandemic on-site activities.

Participant flow

From the start of the trial, only 6 patients were randomized. With low patient recruitment, the BOSTON-4 safety and tolerability study was terminated early on 18 March 2022. This decision was made after a careful and due diligent analysis performed by Zambon of the study status and considering the impact of coronavirus disease 2019 (COVID-19) pandemic on sites activities. So, due to this low recruitment, the Sponsor decided to early terminate the trial, on 18 March 2022.

Participant flow — Overall Study
MilestoneL-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of Care
Started222
Completed222
Not completed000

Outcome measures

PrimaryNumber of Local Tolerability Events of Interest From Baseline to Visit 3 (Week 4)

The local tolerability events of interest taken into consideration were: Cough, Wheezing, Bronchospasm, Throat irritation and Change from baseline in FEV1 to Visit 3.

Time frame:
at Week 4 (visit 3)
Reported as:
Number · number of local events
Number of Local Tolerability Events of Interest From Baseline to Visit 3 (Week 4)
number of local eventsL-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of Care
Any Local Tolerability Event154
Cough011
Wheezing000
Bronchospasm000
Throat irritation132
Change in FEV1011
PrimaryNumber of Participants With AE and sAE of Different Level of Severity During the First 4 Weeks of Treatment

An adverse event (AE) is any untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.

Time frame:
During the first 4 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With AE and sAE of Different Level of Severity During the First 4 Weeks of Treatment
ParticipantsL-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of Care
Any TEAEs111
Mild TEAEs111
Moderate TEAEs000
Severe TEAEs000
Serious TEAEs000
Related TEAEs111
COVID-19 related TEAEs000
Patients discontinued study due to TEAEs000
Patients discontinued treatment due to TEAEs000
TEAEs Leading to Death000
SecondaryNumber of Local Tolerability Events of Interest From Baseline to Week 12

The local tolerability events of interest taken into consideration were: Cough, Wheezing, Bronchospasm, Throat irritation and Change from baseline in FEV1 to Visit 3.

Time frame:
at Week 12
Reported as:
Number · number of events
Number of Local Tolerability Events of Interest From Baseline to Week 12
number of eventsL-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of Care
Any Local Tolerability Event176
Cough022
Wheezing000
Bronchospasm000
Throat irritation143
Change in FEV1011
SecondaryNumber of Participants With AE and sAE of Different Level of Severity During the First 12 Weeks of Treatment

An adverse event (AE) is any untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.

Time frame:
During the first 12 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With AE and sAE of Different Level of Severity During the First 12 Weeks of Treatment
ParticipantsL-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of Care
Any TEAEs211
Mild TEAEs211
Moderate TEAEs100
Severe TEAEs000
Serious TEAEs100
Related TEAEs111
COVID-19 related TEAEs000
Patients discontinued study due to TEAEs000
Patients discontinued treatment due to TEAEs100
TEAEs Leading to Death000
SecondaryCsA Whole Blood Concentrations and CsA Whole Blood Trough Levels

Whole Blood concentrations (Week 0) are at pre-dose, directly after end of inhalation, 15, 30, and 45 minutes, and 1, 1.5, 2, and 4 hours after end of inhalation, and whole blood trough levels (CsA concentration) at Weeks 2, 4, 8, and 12 were calculated.

Time frame:
Weeks 0 (pre-dose, directly after end of inhalation, 15, 30, 45, 60 min, 1.5 h, 2h, 4h), 2, 4, 8, and 12
Reported as:
Mean · ng/ml
CsA Whole Blood Concentrations and CsA Whole Blood Trough Levels
ng/mlL-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of Care
Week 0 - predose12.2115 ± 17.269670.0000 ± 0.000011.7750 ± 16.65236
Directly after end of inhalation84.6510 ± 69.8282119.3420 ± 15.9198012.1760 ± 17.21946
15 min73.5110 ± 59.8212330.0500 ± 24.3400311.2440 ± 15.90142
30 min68.3640 ± 60.5622826.9400 ± 22.1918413.1780 ± 18.63651
45 min70.1555 ± 64.8848323.2780 ± 18.5276113.3145 ± 18.82955
1 hour117.8030 ± NA19.4395 ± 18.1563814.0835 ± 19.91708
1.5 hours115.4350 ± NA16.0300 ± 13.3487613.0425 ± 18.44488
2 hours67.0700 ± 71.4658713.4045 ± 10.8053010.9615 ± 15.50190
4 hours33.3425 ± 35.735068.3950 ± 8.099207.6615 ± 10.83500
Whole Blood Trough Levels - Week 248.6725 ± 64.651484.6365 ± 3.625346.0500 ± 8.55599
Whole Blood Trough Levels - Week 416.2465 ± 17.3304816.8475 ± 21.287456.3000 ± 8.90955
Whole Blood Trough Levels - Week 818.7280 ± 26.485399.0405 ± 3.168554.9500 ± 7.00036
Whole Blood Trough Levels - Week 1223.0195 ± 32.554490.0000 ± NA4.9500 ± 7.00036

Adverse events

Collected over Throughout the complete clinical trial period, i.e. up to week 14 (visit 6 / EoS).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
L-CsA 10 mg Plus Standard of Care0/2 (0%)1/2 (50%)2/2 (100%)
L-CsA 5 mg Plus Standard of Care0/2 (0%)0/2 (0%)1/2 (50%)
Liposomal Placebo Plus Standard of Care0/2 (0%)0/2 (0%)1/2 (50%)
Most frequent serious events
Most frequent serious events
EventL-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of Care
moderate acute respiratory failureRespiratory, thoracic and mediastinal disorders1/20/20/2
Most frequent other events
Most frequent other events
EventL-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of Care
Throat irritationRespiratory, thoracic and mediastinal disorders1/21/21/2
CoughRespiratory, thoracic and mediastinal disorders0/21/21/2
Productive coughRespiratory, thoracic and mediastinal disorders0/21/20/2
WheezingRespiratory, thoracic and mediastinal disorders1/20/20/2
Muscle spasmsMusculoskeletal and connective tissue disorders1/20/20/2

Baseline characteristics

The Safety Analysis Set (SAF) was defined as all randomized patients who had received a partial dose of IMP at least once.

Age, Categorical
Age, Categorical(Participants)L-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of CareTotal
<=18 years0000
Between 18 and 65 years2226
>=65 years0000
Age, Continuous
Age, Continuous(years)L-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of CareTotal
Mean55.5 ± 0.7163.0 ± 0.0046.0 ± 12.7354.8 ± 9.52
Sex: Female, Male
Sex: Female, Male(Participants)L-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of CareTotal
Female0213
Male2013
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)L-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of CareTotal
Hispanic or Latino0112
Not Hispanic or Latino0011
Unknown or Not Reported2103
Region of Enrollment
Region of Enrollment(participants)L-CsA 10 mg Plus Standard of CareL-CsA 5 mg Plus Standard of CareLiposomal Placebo Plus Standard of CareTotal
France1102
Germany1012
Spain0112
08

Study locations

17 sites
  • CHU Hôpital Sud
    Amiens, France
  • Centre Hospitalier Universitaire d'Angers
    Angers, France
  • Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon
    La Tronche, France
  • Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
    Lille, France
  • CHU de Nancy, Hopital Brabois
    Nancy, France
  • CHU de Nantes - Hotel-Dieu
    Nantes, France
  • Hopital Saint Louis
    Paris, France
  • CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque
    Pessac, France
  • St.-Johannes-Hospital
    Dortmund, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Germany
  • Universitätsklinikum Köln
    Köln, Germany
  • Universitätsklinikum Münster
    Münster, Germany
  • Hospital Clinic i Provincial
    Barcelona, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Jun 2022, 28 months.

Results were first posted in Oct 2023, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2019
First posted
Sep 27, 2019
StartActual
Feb 11, 2020
Primary completionActual
Jun 16, 2022
CompletionActual
Dec 15, 2022
Results first posted
Oct 3, 2023
Last update
Oct 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04107675
Lead sponsor
Zambon SpA
Responsible party
Sponsor
First posted
Sep 27, 2019
Start date
Feb 11, 2020
Primary completion
Jun 16, 2022
Completion
Dec 15, 2022
Results posted
Oct 3, 2023
Last update
Oct 3, 2023

Study contacts

Paola Castellani, MD
study director · Zambon SpA, Chief Medical Officer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion